MedTrace Logo

Long Term Follow Up KET-PD

NCT06164756 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-07-11

No results posted yet for this study

Summary

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

Conditions

Interventions

OTHER

Cognitive Behavior Therapy (CBT)

Participants will receive 10 weeks of CBT

OTHER

Treatment As Usual (TAU)

Participants will receive standard of care treatment

Sponsors & Collaborators

  • Fox (Michael J.) Foundation for Parkinson's Research

    collaborator UNKNOWN

  • Yale School of Medicine Center for Brain Mind Health

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Sophie E. Holmes, PhD · Yale University

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-18
Primary Completion
2025-12-21
Completion
2025-12-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06164756 on ClinicalTrials.gov